ADARx Pharmaceuticals upsized its IPO and raised additional cash through a private placement with partner AbbVie. Lead ADARx program onvuzosiran is in Phase 3 testing for the rare disease hereditary angioedema, and the RNA therapies pipeline also spans immunological disorders, cardiovascular diseases and obesity, and neurodegeneration.
Amgen’s dazodalibep led to statistically significant and clinically meaningful results, according to preliminary Phase 3 results in Sjögren's disease. This fusion protein could compete against a Novartis antibody under an FDA review that could make it the first Sjögren's therapy.
Veradigm examines key clinical trends, comorbidity profiles, and treatment trends across adolescence, reproductive years, and peri-/post-menopause. Download it today!
Ayble Health’s Series A round was led by Neon, with participation from Unum Ventures, Upfront Ventures, M13, Cleveland Clinic Ventures, DigiTx and Accomplice.
Ionis Pharmaceuticals’ zilganersen, brand name Zanvastro, is the first disease-modifying therapy approved for the neurological disorder Alexander disease. While Ionis has experience developing medicines for rare neuroscience indications, Zanvastro will be the first neurology product the company brings to the market without a commercialization partner.
Thyme Care's Series E round was led by Morgan Health and included participation from Humana, CVS Health Ventures, AlleyCorp, HealthQuest Capital, Foresite Capital, Concord Health Partners, Frist Cressey Ventures, Town Hall Ventures and a16z Bio + Health.
In a mid-stage study, Teva’s drug prevented intestinal damage in celiac disease patients who underwent a gluten challenge — eating food with gluten to see if it prompts an immune response. There are currently no FDA-approved drugs for celiac disease, but Teva’s antibody is part of a competitive race to bring patients the first one.
Healthcare payments are no longer about transactions. It’s about controlling the revenue cycle. And increasingly, that control is not sitting with ISOs.